Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 06, 2018 16:05 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today announced that the compensation committee of its board of directors approved the grant on Feb. 2, 2018 of...
Horizon Pharma plc Announces the Launch of “Cystinosis United” to Educate, Inspire and Connect the Cystinosis Community
January 30, 2018 08:30 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Jan. 30, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today announced the launch of Cystinosis United, an initiative created for people living with nephropathic...
Horizon Pharma plc to Release Fourth-Quarter and Full-Year 2017 Financial Results and Host Webcast on Feb. 28, 2018
January 29, 2018 08:00 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP) announced today that its fourth-quarter and full-year 2017 financial results will be released on Wednesday, Feb....
Horizon Pharma plc Increases Peak Net Sales Guidance for Key Growth Drivers and Announces Rheumatology and Orphan Pipeline Developments
January 08, 2018 07:05 ET
|
Horizon Pharma plc
-- Increases KRYSTEXXA® (pegloticase injection) Estimated Peak Annual Net Sales to more than $750 Million ---- Increases Teprotumumab Estimated Peak Annual Net Sales to more than $750 Million ----...
Horizon Pharma plc Announces Agreement to License Pre-Clinical Uricase Derivative (MEDI4945) from MedImmune
January 08, 2018 07:00 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), today announced that it has licensed the global rights to MEDI4945, a pre-clinical, genetically engineered...
Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 05, 2018 16:05 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Jan. 05, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today announced that the compensation committee of its board of directors approved the grant on January 4, 2018 of...
Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 04, 2018 07:30 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today announced that the compensation committee of its board of directors approved the grant on Jan. 1, 2018 of...
Horizon Pharma plc Announces FDA Approval to Expand the Indication for PROCYSBI® (cysteamine bitartrate) Delayed-Release Capsules to Include Children One Year of Age and Older Living with Nephropathic Cystinosis
December 27, 2017 08:00 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Dec. 27, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today announced the U.S. Food and Drug Administration (FDA) has approved an expansion to the indication for...
Horizon Pharma plc to Present at the 36th Annual J.P. Morgan Healthcare Conference
December 18, 2017 09:23 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Dec. 18, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
December 05, 2017 16:05 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and...